BR112017005120A2 - composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo - Google Patents
composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduoInfo
- Publication number
- BR112017005120A2 BR112017005120A2 BR112017005120-6A BR112017005120A BR112017005120A2 BR 112017005120 A2 BR112017005120 A2 BR 112017005120A2 BR 112017005120 A BR112017005120 A BR 112017005120A BR 112017005120 A2 BR112017005120 A2 BR 112017005120A2
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- inducing antibodies
- therapeutic
- composition
- therapeutic conjugate
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 230000003111 delayed effect Effects 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001173—Globo-H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
a presente descrição abrange composições imunogênicas/terapêuticas incluindo glicoconjugados globo h ?lkh (obi-822) e/ou adjuvantes terapêuticos (obi-821/bi-834) bem como métodos para fazer e utilizar os mesmos para tratar doenças proliferativas tais como câncer. o conjugado terapêutico inclui um antígeno ligado a um veículo. em particular, o conjugado terapêutico inclui uma porção globo h e uma porção klh e/ou uma subunidade da porção klh derivada, opcionalmente ligada via um ligante. as composições terapêuticas são, em parte, previstas para agir como vacinas de câncer para estimular a capacidade natural do corpo para proteger a si mesmo, através do sistema imune a partir de perigos apresentados por células danificadas ou anormais, tais como células cancerígenas. respostas imunes exemplificativas podem ser caracterizadas pela redução da severidade da doença, incluindo, mas não limitado a, prevenção da doença, retardo do início da doença, diminuição da severidade dos sintomas, diminuição da morbidade e retardo na mortalidade.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050567P | 2014-09-15 | 2014-09-15 | |
| US62/050,567 | 2014-09-15 | ||
| PCT/US2015/050270 WO2016044326A1 (en) | 2014-09-15 | 2015-09-15 | Immunogenic/therapeutic glycoconjugate compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112017005120A2 true BR112017005120A2 (pt) | 2018-01-23 |
| BR112017005120B1 BR112017005120B1 (pt) | 2021-01-05 |
Family
ID=55533765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017005120-6A BR112017005120B1 (pt) | 2014-09-15 | 2015-09-15 | composição |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160339089A1 (pt) |
| EP (1) | EP3193919B1 (pt) |
| JP (1) | JP6774941B2 (pt) |
| KR (2) | KR20230109783A (pt) |
| CN (1) | CN107427564A (pt) |
| AR (1) | AR101871A1 (pt) |
| AU (1) | AU2015317889B2 (pt) |
| BR (1) | BR112017005120B1 (pt) |
| CA (1) | CA2961522A1 (pt) |
| CL (1) | CL2017000625A1 (pt) |
| ES (1) | ES2797747T3 (pt) |
| IL (1) | IL251120B (pt) |
| MY (1) | MY188880A (pt) |
| PH (1) | PH12017500478A1 (pt) |
| RU (1) | RU2720295C2 (pt) |
| SG (1) | SG11201702037SA (pt) |
| TW (1) | TWI726850B (pt) |
| WO (1) | WO2016044326A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| MY200886A (en) * | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| AU2017302038B2 (en) * | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| KR102528998B1 (ko) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | 인간 항체, 제약 조성물 및 방법 |
| TWI767959B (zh) | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| WO2019217951A1 (en) * | 2018-05-11 | 2019-11-14 | Obi Pharma Inc. | Method for predicting human immune response |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7824687B2 (en) * | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
| US7854934B2 (en) * | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
| CA2454853A1 (en) * | 2001-08-14 | 2003-02-27 | Biomira, Inc. | Imunogenic conjugate of carbohydrate haptens and aggregated protein carrier |
| CN102065868A (zh) * | 2008-06-16 | 2011-05-18 | 中央研究院 | 诱发对于Globo H及SSEA3的特异免疫反应的组合物以及其在癌症治疗中的用途 |
| CN102215862B (zh) * | 2009-06-16 | 2016-04-06 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
| EP2500035A1 (en) * | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
| KR101806370B1 (ko) * | 2013-01-04 | 2017-12-07 | 오비아이 파머 인코퍼레이티드 | 보다 높은 탄수화물 항원 밀도 및 신규한 사포닌 애쥬번트를 갖는 백신 |
| CN105764921B (zh) * | 2013-09-17 | 2020-06-30 | 台湾浩鼎生技股份有限公司 | 用于诱导免疫反应的糖疫苗组合物及其治疗癌症的用途 |
-
2015
- 2015-09-15 KR KR1020237023433A patent/KR20230109783A/ko not_active Application Discontinuation
- 2015-09-15 RU RU2017112982A patent/RU2720295C2/ru active
- 2015-09-15 BR BR112017005120-6A patent/BR112017005120B1/pt active IP Right Grant
- 2015-09-15 JP JP2017514552A patent/JP6774941B2/ja active Active
- 2015-09-15 US US14/855,260 patent/US20160339089A1/en active Pending
- 2015-09-15 SG SG11201702037SA patent/SG11201702037SA/en unknown
- 2015-09-15 AR ARP150102941A patent/AR101871A1/es unknown
- 2015-09-15 WO PCT/US2015/050270 patent/WO2016044326A1/en active Application Filing
- 2015-09-15 TW TW104130500A patent/TWI726850B/zh active
- 2015-09-15 CN CN201580062962.2A patent/CN107427564A/zh active Pending
- 2015-09-15 ES ES15842660T patent/ES2797747T3/es active Active
- 2015-09-15 AU AU2015317889A patent/AU2015317889B2/en active Active
- 2015-09-15 CA CA2961522A patent/CA2961522A1/en active Pending
- 2015-09-15 EP EP15842660.1A patent/EP3193919B1/en active Active
- 2015-09-15 MY MYPI2017000385A patent/MY188880A/en unknown
- 2015-09-15 KR KR1020177009879A patent/KR20170090405A/ko not_active Application Discontinuation
-
2017
- 2017-03-13 IL IL251120A patent/IL251120B/en active IP Right Grant
- 2017-03-13 PH PH12017500478A patent/PH12017500478A1/en unknown
- 2017-03-14 CL CL2017000625A patent/CL2017000625A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6774941B2 (ja) | 2020-10-28 |
| BR112017005120B1 (pt) | 2021-01-05 |
| PH12017500478A1 (en) | 2017-07-10 |
| EP3193919A1 (en) | 2017-07-26 |
| AU2015317889B2 (en) | 2021-06-03 |
| EP3193919A4 (en) | 2018-04-18 |
| KR20170090405A (ko) | 2017-08-07 |
| ES2797747T3 (es) | 2020-12-03 |
| RU2720295C2 (ru) | 2020-04-28 |
| JP2017532310A (ja) | 2017-11-02 |
| TW201628646A (zh) | 2016-08-16 |
| CL2017000625A1 (es) | 2018-02-02 |
| SG11201702037SA (en) | 2017-04-27 |
| US20160339089A1 (en) | 2016-11-24 |
| EP3193919B1 (en) | 2020-04-08 |
| RU2017112982A3 (pt) | 2019-04-24 |
| WO2016044326A1 (en) | 2016-03-24 |
| KR20230109783A (ko) | 2023-07-20 |
| IL251120B (en) | 2021-05-31 |
| AU2015317889A1 (en) | 2017-04-13 |
| MY188880A (en) | 2022-01-12 |
| WO2016044326A9 (en) | 2017-05-11 |
| CA2961522A1 (en) | 2016-03-24 |
| RU2017112982A (ru) | 2018-10-17 |
| TWI726850B (zh) | 2021-05-11 |
| CN107427564A (zh) | 2017-12-01 |
| IL251120A0 (en) | 2017-04-30 |
| AR101871A1 (es) | 2017-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017005120A2 (pt) | composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo | |
| BR112019001656A2 (pt) | composição, composição farmacêutica, vacina, método para induzir anticorpos em um indivíduo, método para tratar câncer em um paciente necessitando do mesmo e método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo | |
| BR112015032713A2 (pt) | composto; composição terapêutica; composição farmacêutica; método para tratar o câncer em um paciente em necessidade; e método para induzir anticorpos em um animal ou um humano para a finalidade de criar anticorpos monoclonais para usos terapêuticos ou diagnósticos | |
| MX2018010586A (es) | Nanovacuna de activacion de "sting" para inmunoterapia. | |
| NI202000040A (es) | Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos | |
| PE20191081A1 (es) | Nuevos receptores de celulas t y terapia inmunologica que los utiliza | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| MX2019010460A (es) | Plataforma de identificacion de peptidos inmunogenicos basada en poblacion. | |
| BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
| MX2015013235A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| ZA202206809B (en) | Hiv vaccines comprising one or more population episensus antigens | |
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| BR112019008844A2 (pt) | conjugado de proteína de polissacarídeo imunogênico compreendendo um polissacarídeo derivado de b. streptococcus gbs | |
| NZ731659A (en) | Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| PH12015502844A1 (en) | Mammalian milk osteopontin for enhancing immune responsiveness | |
| BR112022006177A2 (pt) | Kir3dl3 é um receptor inibidor do sistema imune e do mesmo | |
| BR112017002206A2 (pt) | peptídeo derivado de koc1 e vacina incluindo o mesmo | |
| MX2021001288A (es) | Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer. | |
| RU2018123307A (ru) | Вакцинация с использованием альфа3 домена mica/b для лечения рака | |
| WO2022238381A3 (en) | Immunotherapy constructs for treatment of disease | |
| WO2009117365A3 (en) | Vaccine compositions for inducing immune responses against components of drusen | |
| AR083721A1 (es) | VACUNA DE PEPTIDO DE IgE DE DOMINIO CONSTANTE (CH) | |
| TH154722A (th) | องค์ประกอบของเพปไทด์ที่มีส่วนร่วมกับเนื้องอกและวัคซีนต้านมะเร็งที่สัมพันธ์กันสำหรับการบำบัดของมะเร็งกระเพาะอาหารและมะเร็งอื่นๆ | |
| TH1701000387A (th) | องค์ประกอบ lhrh สำหรับการก่อภูมิคุ้มกันและการใช้องค์ประกอบนั้นในสุกร |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B65X | Notification of requirement for priority examination of patent application | ||
| B65Y | Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117) | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/09/2015, OBSERVADAS AS CONDICOES LEGAIS. |